Class summary at a glance.

Every drug in the Insulin Analog class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 16tracked in Part D
CY24 Part D spend: $5.21Bcombined across class
Total Rx claims: 14.1M5.3M unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Insulin Degludec

Brand: TRESIBA · 3.5M Part D claims (CY24) · 1.2M beneficiaries · First FDA approval: 2015-09-25

Brand-only (no generics) 3 plans require PA Discontinued

Low NADAC$9.02

→

Avg plan cost$13.60

Part D spend $2.69B 2× spread, current vs floor

Class share

52%

of class CY24 spend

View profile →

Insulin Lispro

Brand: ADMELOG · 5.2M Part D claims (CY24) · 2.0M beneficiaries · First FDA approval: 1996-06-14

Brand-only (no generics) 100 plans require PA Discontinued

Low NADAC$2.40

→

Avg plan cost$10.16

Part D spend $1.35B 4× spread, current vs floor

Class share

26%

of class CY24 spend

View profile →

Insulin Aspart

Brand: .Insulin Aspart Protamine and Insulin Aspart · 3.4M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 2001-08-27

Brand-only (no generics) 92 plans require PA Discontinued

Low NADAC$6.94

→

Avg plan cost$8.12

Part D spend $704.9M 1× spread, current vs floor

Class share

14%

of class CY24 spend

View profile →

Insulin Glargine-Yfgn

Brand: INSULIN GLARGINE · 1.1M Part D claims (CY24) · 515K beneficiaries · First FDA approval: 2023-07-28

Brand-only (no generics) 0 plans require PA

Low NADAC$2.89

→

Avg plan cost$11.59

Part D spend $168.2M 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Insulin Detemir

Brand: LEVEMIR · 725K Part D claims (CY24) · 275K beneficiaries · First FDA approval: 2006-03-27

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $155.5M

Class share

of class CY24 spend

View profile →

Insulin Lispro-Aabc

Brand: LYUMJEV · 154K Part D claims (CY24) · 56K beneficiaries · First FDA approval: 2020-06-15

Brand-only (no generics) 33 plans require PA Discontinued

Low NADAC$7.89

→

Avg plan cost$12.13

Part D spend $139.8M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Insulin Glulisine

Brand: Apidra · 15K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2009-02-24

Brand-only (no generics) 3 plans require PA

Low NADAC$8.17

→

Avg plan cost$9.34

Part D spend $4.4M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Insulin Glargine-Aglr

Brand: REZVOGLAR KWIKPEN · 13K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2021-12-17

Brand-only (no generics) 1 plans require PA

Low NADAC$5.92

→

Avg plan cost$5.92

Part D spend $1.1M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Diluent

Brand: Sterile Diluent · — Part D claims (CY24) · First FDA approval: 1987-07-10

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Insulin Aspart Injection

Brand: Fiasp · — Part D claims (CY24) · First FDA approval: 2017-10-20

Brand-only (no generics) 91 plans require PA

Low NADAC$6.93

→

Avg plan cost$8.15

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Insulin Aspart-Szjj

Brand: MERILOG · — Part D claims (CY24) · First FDA approval: 2025-02-14

Brand-only (no generics) 1 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Insulin Aspart-Xjhz

Brand: KIRSTY · — Part D claims (CY24) · First FDA approval: 2025-09-15

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Insulin Degludec and Liraglutide

Brand: Xultophy 100/3.6 · — Part D claims (CY24) · First FDA approval: 2016-11-21

Brand-only (no generics) 0 plans require PA

Low NADAC$85.86

→

Avg plan cost$85.86

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Insulin Glargine

Brand: BASAGLAR · — Part D claims (CY24) · First FDA approval: 2009-09-23

Brand-only (no generics) 3 plans require PA Discontinued

Low NADAC$6.16

→

Avg plan cost$39.47

Part D spend — 6× spread, current vs floor

Class share

of class CY24 spend

View profile →

Insulin Glargine and Lixisenatide

Brand: Soliqua 100/33 · — Part D claims (CY24) · First FDA approval: 2016-11-21

Brand-only (no generics) 0 plans require PA

Low NADAC$57.05

→

Avg plan cost$57.05

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Water Injection

Brand: Insulin Diluting Medium for NovoLog · — Part D claims (CY24) · First FDA approval: 2001-08-27

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.